Recombinant Adenovirus Vectors Expressing Interleukin-5 and -6 Specifically Enhance Mucosal Immunoglobulin A Responses in the Lung
Overview
Affiliations
In this study, we have examined the in vivo effects of interleukin-5 (IL-5) and IL-6 over-expression on systemic and mucosal immune responses using recombinant human type 5 adenoviruses capable of expressing these cytokines upon infection. A recombinant adenovirus containing the murine IL-5 gene within the E3 region was constructed and found to express high levels of IL-5 protein both in vitro and in vivo. Intranasal inoculation of mice with this vector or a vector expressing murine IL-6 increased adenovirus-specific immunoglobulin A (IgA) titres in lung lavage fluid threefold compared with those elicited by control virus. The simultaneous expression of both cytokines by co-inoculation altered the kinetics of the mucosal anti-adenovirus IgA response and resulted in a more than additive increase in antibody titres. The co-expression effect on IgA synthesis was not due to an increase in numbers of antigen-specific resident lung tissue lymphocytes. When mucosal IgG responses were examined, IL-6 expression had the largest impact on anti-adenovirus levels, whereas co-expression produced an intermediate response. Systemic immune responses were also affected by IL-6 expression as a twofold increase in serum IgG anti-adenovirus titres was observed after a secondary challenge with wild-type adenovirus. These results demonstrate a relevant role for IL-5 and IL-6 in the development of mucosal immune responses in vivo and suggest that the incorporation of either IL-5 and/or IL-6 into recombinant adenovirus vectors may be a useful tool in the development of mucosal vaccines.
Wang L, Kang J, Jiang H Vaccines (Basel). 2024; 12(9).
PMID: 39340053 PMC: 11436211. DOI: 10.3390/vaccines12091022.
Lopez-Cano A, Bach A, Lopez-Serrano S, Aragon V, Blanch M, Pastor J Animals (Basel). 2022; 12(9).
PMID: 35565502 PMC: 9101217. DOI: 10.3390/ani12091075.
Innate endogenous adjuvants prime to desirable immune responses via mucosal routes.
Wang X, Meng D Protein Cell. 2014; 6(3):170-84.
PMID: 25503634 PMC: 4348248. DOI: 10.1007/s13238-014-0125-1.
Bovine adenovirus-3 as a vaccine delivery vehicle.
Ayalew L, Kumar P, Gaba A, Makadiya N, Tikoo S Vaccine. 2014; 33(4):493-9.
PMID: 25498212 PMC: 7115382. DOI: 10.1016/j.vaccine.2014.11.055.
Cytokines: the future of intranasal vaccine adjuvants.
Thompson A, Staats H Clin Dev Immunol. 2011; 2011:289597.
PMID: 21826181 PMC: 3150188. DOI: 10.1155/2011/289597.